MedAll

💊 Calling all hematology-oncology clinicians—we’d value your input. In your practice, to what extent is translating evolving evidence and treatment guidance into routine care for patients with B-cell non-Hodgkin lymphoma a challenge?

🧬 HCPs, we'd value your perspective We're exploring biomarker-guided care in metastatic hormone-sensitive prostate cancer. Is the following a gap in clinical practice? Implementing molecular biomarker testing and integrating results to guide personalised treatment selection.

👋HCP perspectives wanted We’re exploring best practice in managing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Is the following a gap in clinical practice? Clinicians lack confidence in predicting disease progression and relapse in patients with CIDP.

📊HCPs insight wanted We’re exploring the management of transthyretin amyloidosis-cardiomyopathy across APAC. Is the following a gap in clinical practice? Consistent differential diagnosis using guideline-recommended techniques

⁉️Question for HCPs We’re exploring the management of pediatric myopia. Is the following a gap in clinical practice? Lack of consistency in identifying risk, who to treat and how to monitor progression

📊HCP perspectives wanted We are exploring safety monitoring for emerging ADC therapies. As this evidence emerges, is this a gap for you? Formulating anticipatory monitoring for CDH6-directed ADCs, beyond general DXd-class effects.

🩺HCPs, we’d love to hear from you We’re exploring educational needs in GEP-NETs Is the following a gap in clinical practice? Uncertainty around sequencing systemic and radioligand therapies, leading to inconsistent treatment pathways.

👋 HCPs, can you help? We're exploring presbyopia-correcting IOL selection. Is the following a gap in clinical practice? Individualizing optical targets for patients receiving presbyopia-correcting IOLs by integrating ocular measurements with patient-specific factors:

HCPs! We’re exploring PI3k-inhibitors in HR+/HER2- metastatic breast cancer. Is the following a gap in clinical practice? Uncertainty in applying clinical evidence on efficacy, safety, trial populations, and real‑world tolerability to patient selection and treatment decisions.

📣Calling all HCPs We’re exploring global MASH care. Is the following a gap in clinical practice? Unclear referral thresholds and multidisciplinary team roles can delay specialist review, monitoring, and coordinated follow-up of patients with MASH.

⁉️Quick question for clinicians We’re exploring global MASH care. Is the following a gap in clinical practice? Clinicians may lack confidence interpreting evolving MASH evidence and applying guideline directed and/or approved treatments in clinical practice

📊HCP perspectives wanted We’re exploring global MASH care. Is the following a gap in clinical practice? At-risk patients are not consistently recognized by clinicians, and fibrosis risk is not routinely assessed using FIB-4 followed by a second-line test.

👋HCPs, we want to hear from you We’re exploring global MASH care. Is the following a gap in clinical practice? Clinicians underestimate MASH progression and fibrosis-related hepatic and cardiometabolic risk.

💡 HCPs can you help? We're exploring treatment decision-making in gastrointestinal stromal tumours. Is the following a gap in clinical practice? Applying emerging clinical evidence to personalise treatment selection for patients with advanced gastrointestinal stromal tumours

📣Calling all HCPs We're exploring MOGAD diagnosis and management. Is the following a gap in clinical practice? HCPs lack confidence using MOG-IgG testing protocols and referral pathways to neuroimmunology.

📊HCP perspectives wanted We’re exploring readiness for CAR T-cell therapy in Autoimmune Rheumatic Diseases. Is this a gap in clinical practice? HCPs face challenges distinguishing CAR T-cell therapy toxicities from autoimmune disease flares.

📊Clinician insights wanted We're exploring developmental and epileptic encephalopathies (DEEs). Is this a gap in practice? HCPs lack confidence optimising treatment to reduce polypharmacy and drug interactions while maintaining symptom control.

🩺Pharmacists we want to hear from you We're exploring safety monitoring for new FSGS agents. Is the following a gap in clinical practice? Limited familiarity with monitoring and counseling for approved and emerging FSGS agents-what to watch for and how to support adherence.

📚 Calling all healthcare professionals, we'd value your perspective. How challenging is it to integrate disease characteristics, biomarker results, and emerging evidence when planning treatment for head and neck squamous cell carcinoma?

🧬 Calling all healthcare professionals, we'd value your perspective. How challenging is it to integrate HPV/p16 and PD-L1 test results into multidisciplinary treatment planning and referral decisions?